Once-daily dosing with or without food

  • The starting dose is 1.5 mg on Day 1 and should be increased to 3 mg on Day 21
  • Further dose adjustments can be made in 1.5-mg or 3-mg increments, up to a maximum recommended dose of 6 mg/day, depending on clinical response and tolerability1
    • In short-term controlled studies, doses above 6 mg/day did not confer increased effectiveness sufficient to outweigh dose-related adverse reactions
  • Because of the long half-life of cariprazine and its active metabolites, changes in dose will not be fully reflected in plasma for several weeks. Monitor patients for adverse reactions and treatment response for several weeks after starting VRAYLAR and after each dosage change1
  • Following discontinuation of VRAYLAR, the decline in plasma concentrations of active drug and metabolites may not be immediately reflected in patients’ clinical symptoms1
    • The decline in plasma concentrations of active drug and metabolites may not be immediately reflected in patients’ clinical symptoms.
  • There are no systematically collected data to specifically address switching patients from VRAYLAR to other antipsychotics or concerning concomitant administration with other antipsychotics1

Available in 4 dosage strengths1

Not actual size.

Drug interactions and dosage adjustments

  • No dosage adjustment is required based on patient’s age, sex, race, or smoking status or for mild to moderate hepatic and renal impairment1
    • VRAYLAR is not recommended in patients with severe hepatic (Child-Pugh score 10-15) or renal impairment (creatinine clearance < 30 mL/min), as it has not been evaluated in these patient populations
  • Cariprazine is extensively metabolized into 2 active metabolites, desmethyl cariprazine (DCAR) and didesmethyl cariprazine (DDCAR) by CYP3A4 and, to a lesser extent, by CYP2D61
  • Clinically significant drug interactions and dosage adjustments with VRAYLAR1
    • CYP3A4 is responsible for the formation and elimination of the active metabolites of cariprazine


  • VRAYLAR is unlikely to cause clinically significant pharmacokinetic drug interactions with substrates of the following (based on in vitro studies)1:

    • CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E, or CYP3A4
    • OATP1B1, OATP1B3, BCRP, OCT2, OAT1, or OAT3
  • Each dosage strength is available in 30-count bottles

  • For more information, contact Allergan Customer Relations and Medical Affairs at 1-800-678-1605